{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:23:45Z","timestamp":1790645025366,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"The Krembil Neurosciences Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.eplepsyres.2014.08.009","type":"journal-article","created":{"date-parts":[[2014,8,30]],"date-time":"2014-08-30T16:32:38Z","timestamp":1409416358000},"page":"1642-1651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-4700","authenticated-orcid":false,"given":"Felippe","family":"Borlot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Wither","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anfal","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1072-1077","authenticated-orcid":false,"given":"Nicky","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Verocai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yebeh.2013.07.006","article-title":"Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: a pilot study","volume":"29","author":"Asadi-Pooya","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0010","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0015","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0020","first-page":"2212","article-title":"Oxcarbazepine in a monotherapy trial for partial seizures \u2013 placebo-controlled studies in neurology: where do they stop?","volume":"53","author":"Cramer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0025","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1212\/WNL.57.10.1774","article-title":"Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures","volume":"57","author":"Faught","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2014.08.009_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2007.00992.x","article-title":"Refractory epilepsy: clinical overview","volume":"48","author":"French","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.CON.0000431380.21685.75","article-title":"Antiepileptic drug treatment: new drugs and new strategies","volume":"19","author":"French","year":"2013","journal-title":"Continuum"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0040","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1528-1167.2009.02428.x","article-title":"Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow","volume":"51","author":"Ghosh","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0045","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1528-1167.2010.02956.x","article-title":"Cellular localization and functional significance of CYP3A4 in the human epileptic brain","volume":"52","author":"Ghosh","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0050","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/epi.12318","article-title":"Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains","volume":"54","author":"Ghosh","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2009.02.014","article-title":"Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy","volume":"85","author":"Iannetti","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0060","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1528-1167.2005.59204.x","article-title":"Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus","volume":"46","author":"Iannetti","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0065","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.0013-9580.2005.31904.x","article-title":"Potential role of drug transporters in the pathogenesis of medically intractable epilepsy","volume":"46","author":"Kwan","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0070","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/jnnp.2004.045690","article-title":"The natural history of epilepsy: an epidemiological view","volume":"75","author":"Kwan","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.eplepsyres.2014.08.009_bib0075","first-page":"3","article-title":"Mechanisms of drug resistance","volume":"7","author":"L\u00f6scher","year":"2005","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0080","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood\u2013brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0085","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(86)91099-8","article-title":"Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction","volume":"1","author":"Macphee","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0090","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1528-1167.2005.35904.x","article-title":"Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine","volume":"46","author":"Majkowski","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-2-37","article-title":"Significance of MDR1 and multiple drug resistance in refractory human epileptic brain","volume":"2","author":"Marchi","year":"2004","journal-title":"BMC Med."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.seizure.2013.09.009","article-title":"Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study","volume":"1","author":"Nicita","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0105","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1111\/j.1468-1331.2011.03513.x","article-title":"Termination of refractory focal status epilepticus by the P-glycoprotein inhibitor verapamil","volume":"18","author":"Pirker","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(02)00423-8","article-title":"P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood\u2013brain barrier: evidence from microdialysis experiments in rats","volume":"327","author":"Potschka","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1046\/j.1528-1157.2001.01901.x","article-title":"In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood\u2013brain barrier of rats","volume":"42","author":"Potschka","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0120","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.yebeh.2010.01.166","article-title":"Verapamil attenuates the malignant treatment course in recurrent status epilepticus","volume":"17","author":"Schmitt","year":"2010","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0125","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","article-title":"Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms","volume":"46","author":"Schmidt","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0130","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa021986","article-title":"Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1","volume":"348","author":"Siddiqui","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/brain\/awf002","article-title":"Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy","volume":"125","author":"Sisodiya","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0140","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1345\/aph.1E068","article-title":"Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy","volume":"38","author":"Summers","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1995.tb01657.x","article-title":"MDR1 gene expression in brain of patients with medically intractable epilepsy","volume":"36","author":"Tishler","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0150","series-title":"Child Neurology Society Meeting, Program and Abstracts","first-page":"34","article-title":"Verapamil as adjunctive therapy for seizures in Dravet syndrome","author":"Wical","year":"2013"},{"key":"10.1016\/j.eplepsyres.2014.08.009_bib0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eplepsyres.2003.12.009","article-title":"Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats","volume":"58","author":"Volk","year":"2004","journal-title":"Epilepsy Res."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114002186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121114002186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:32:02Z","timestamp":1760275922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121114002186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0920121114002186"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.08.009","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}